Oruka Therapeutics (ORKA) News Today $10.95 -0.24 (-2.14%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.53 -0.42 (-3.84%) As of 05/23/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at StockNews.comStockNews.com upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.May 24 at 10:56 AM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Coverage Initiated by Analysts at BTIG ResearchBTIG Research started coverage on shares of Oruka Therapeutics in a report on Thursday. They set a "buy" rating and a $44.00 price objective on the stock.May 24 at 9:26 AM | marketbeat.comFrazier Life Sciences Management L.P. Grows Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Frazier Life Sciences Management L.P. lifted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 22.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 583,327 shares of the company's stock afterMay 23 at 7:51 AM | marketbeat.comVR Adviser LLC Buys 200,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)VR Adviser LLC increased its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,285,620 shares of the company's stock after acquiring an additional 200,000 shares during the periodMay 22 at 6:53 AM | marketbeat.comPoint72 Asset Management L.P. Cuts Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Point72 Asset Management L.P. lessened its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 25.2% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 360,732 shares of the company's stock after selling 1May 22 at 4:42 AM | marketbeat.comOruka Therapeutics begins trial for psoriasis treatmentMay 21, 2025 | uk.investing.comOruka Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 21, 2025 | globenewswire.comOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F AntibodyMay 20, 2025 | globenewswire.comWedbush Predicts Weaker Earnings for Oruka TherapeuticsMay 20, 2025 | americanbankingnews.comWedbush Forecasts Reduced Earnings for Oruka TherapeuticsOruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Analysts at Wedbush reduced their Q2 2025 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will posMay 20, 2025 | marketbeat.comContrasting Oruka Therapeutics (NASDAQ:ORKA) & Trinity Biotech (NASDAQ:TRIB)May 19, 2025 | americanbankingnews.comRTW Investments LP Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)RTW Investments LP grew its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 5.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,945,649 shares of the company's stock after purchasMay 18, 2025 | marketbeat.comPolar Capital Holdings Plc Buys New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Polar Capital Holdings Plc acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 550,000 shares of the company's stock, valued at approximMay 18, 2025 | marketbeat.comJanus Henderson Group PLC Boosts Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Janus Henderson Group PLC increased its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 259.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 849,410May 18, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)May 18, 2025 | americanbankingnews.comTD Cowen Remains a Buy on Oruka Therapeutics (ORKA)May 17, 2025 | theglobeandmail.comWedbush Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)May 17, 2025 | theglobeandmail.comParadigm Biocapital Advisors LP Boosts Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Paradigm Biocapital Advisors LP lifted its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 13.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 819,660 shares of the company's stockMay 16, 2025 | marketbeat.comOruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comJefferies Financial Group Inc. Makes New $6.79 Million Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Jefferies Financial Group Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 350,029 shares of the company's stock, valued at approxiMay 14, 2025 | marketbeat.comFairmount Funds Management LLC Has $65.38 Million Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Fairmount Funds Management LLC lifted its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,371,922 shares of the company's stock after buyingMay 10, 2025 | marketbeat.comDeep Track Capital LP Sells 485,187 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)Deep Track Capital LP lessened its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 39.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 750,000 shares of the company's stock after selling 485,187 shares during the period. Deep TMay 9, 2025 | marketbeat.comBraidwell LP Acquires 631,950 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)Braidwell LP raised its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 122.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,147,676 shares of the company's stock after acquiring an additional 631,950 shares during the perioMay 8, 2025 | marketbeat.comBlackstone Inc. Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Blackstone Inc. bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 240,174 shares of the company's stock, valued at approximately $4,657,000. Blackstone Inc. owned 0.69May 8, 2025 | marketbeat.comBarclays PLC Purchases Shares of 74,583 Oruka Therapeutics, Inc. (NASDAQ:ORKA)Barclays PLC purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 74,583 shares of the company's stock, valued atMay 6, 2025 | marketbeat.com683 Capital Management LLC Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)683 Capital Management LLC bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 33,875 shares of the company's stock, valued at approximately $May 4, 2025 | marketbeat.comQ1 EPS Forecast for Oruka Therapeutics Reduced by AnalystOruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a report released on Monday, April 28th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per sharMay 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Grows Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Price T Rowe Associates Inc. MD increased its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 374.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,326,893 shares of the company's stock after buying an additioMay 3, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Buy" by BrokeragesOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received an average rating of "Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to thMay 3, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ORKA Q1 Earnings?Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Oruka Therapeutics in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.62) pMay 2, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. cut its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 65.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,200 shares of the company's stock after seMay 2, 2025 | marketbeat.comOruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceApril 29, 2025 | globenewswire.comGeode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Geode Capital Management LLC grew its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 2,348.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 342,418 shares of the company's stock after acquiring an additional 328,434 sApril 28, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Bought by SR One Capital Management LPSR One Capital Management LP lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 430,330 shares of the company's stock after acquiring aApril 19, 2025 | marketbeat.comOruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on ThursdayOruka Therapeutics (NASDAQ:ORKA) will be releasing earnings before the market opens on Thursday, April 24, Financial Modeling Prep reports.April 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys Shares of 60,494 Oruka Therapeutics, Inc. (NASDAQ:ORKA)Kennedy Capital Management LLC purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 60,494 shares of the company's stocApril 17, 2025 | marketbeat.comFmr LLC Increases Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Fmr LLC grew its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 17.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,512,300 shares of the company's stock after purchasing anApril 16, 2025 | marketbeat.comVanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)Vanguard Group Inc. boosted its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 4,161.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,610,651 shares of the company's stock after acquiring an additional 1,572,853 shares durinApril 16, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from AnalystsOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are currently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to theApril 7, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the compaMarch 12, 2025 | marketbeat.comWe're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn RateMarch 8, 2025 | finance.yahoo.comOruka Therapeutics' (ORKA) "Outperform" Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner RelianceMarch 8, 2025 | tipranks.comOruka Therapeutics announces preclinical data for ORKA-002March 7, 2025 | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPSOruka Therapeutics (NASDAQ:ORKA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19.March 7, 2025 | marketbeat.comOruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual MeetingMarch 7, 2025 | globenewswire.comOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comOruka Therapeutics sees $1.41 million in stock purchases by Venrock HealthcareMarch 1, 2025 | investing.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in StockOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 8,971 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the transaction, the insider now directly owns 4,044,684 shares in the company, valued at $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.February 28, 2025 | marketbeat.comInsider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of StockOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of Oruka Therapeutics stock in a transaction on Friday, February 14th. The stock was bought at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the acquisition, the insider now directly owns 4,148,428 shares of the company's stock, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.February 28, 2025 | marketbeat.com Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Media Mentions By Week ORKA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORKA News Sentiment▼0.620.75▲Average Medical News Sentiment ORKA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORKA Articles This Week▼153▲ORKA Articles Average Week Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MESO News Today ADPT News Today VERA News Today DYN News Today GPCR News Today ANIP News Today SPRY News Today CALT News Today ETNB News Today OCUL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORKA) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORKA with Qtrade Free ORKA Stock Alerts